相关实验视频

Updated: Jan 16, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

先进的抗体-药物结合体设计:链接器化学和特定站点结合技术的创新

Yutaka Matsuda¹, Jenny R Chang¹, Brian A Mendelsohn¹

¹Discovery Biotherapeutics, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA.

Chembiochem : a European journal of chemical biology

|September 26, 2025

概括

抗体-药物联合体 (ADC) 通过向瘤传递细胞毒性有效载荷,提供向癌症治疗. 最近链接化学和特定位点结合的进展对于提高ADC的疗效和降低毒性至关重要.

科学领域:

在瘤学瘤学.
制药化学制药化学制药化学
生物技术是生物技术.

背景情况:

抗体-药物结合物 (ADC) 是一种向的癌症疗法,可向瘤细胞传递细胞毒性有效载荷 (PL).
已批准的ADC证明了临床成功,但链接器稳定性和结合异质性的挑战仍然存在.
优化ADC设计需要链接器化学和合技术的进步.

研究的目的:

审查最近链接化学和抗体药物联结物 (ADC) 的特定位点联结方面的进展.
讨论克服ADC开发挑战的策略,包括链接器稳定性和有效载荷交付.
突出创新的结合技术,增强ADC的同质性,稳定性和治疗性能.

主要方法:

关于ADC开发中的链接器化学和结合技术的最新文献的审查.
讨论传统与先进的结合方法 (例如, lysine,cysteine, site-specific).
对新型链接器组件,化学手柄,间隔器和释放触发器的分析.

主要成果:

链接器化学的进步,包括可切割的链接器,改善了ADC的临床成功.
特定站点的结合技术 (例如THIOMAB,SMARTag,AJICAP) 提高了ADC的同质性和稳定性.
新策略解决了毒性和非目标效应,改善了治疗指数.

结论:

连接器化学和特定站点的结合对于下一代ADC开发至关重要.
结合技术的创新是优化ADC有效性和安全性的关键.
对ADC链接器和结合策略的进一步研究将促进向癌症治疗.

关键词:

抗体药物联合体抗体药物联合体可以切割的链接器.马利胺替代品马利胺替代品特定地点的结合.

更多相关视频

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition

Published on: December 23, 2016

相关概念视频

Phase II Conjugation Reactions: Overview

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...